LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DexCom, Inc., (“DexCom” or the "Company") (NASDAQ: DXCM) investors off a class action on behalf of investors that bought securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). DexCom investors have until December 26, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal right ...

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.DXCM is lagging behind market performance. Get the complete picture here.A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device.Some patients reportedly experien ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/or f ...

Core Viewpoint - DexCom, Inc. is expected to report strong third-quarter results, driven by operational momentum, patient growth, and improved access, with a raised full-year revenue outlook reflecting confidence in demand and reimbursement expansion [1][2][8] Operational Performance - The company enters Q3 with solid operational momentum, supported by continued patient growth and a strengthening global footprint [2][8] - Commercial execution is a focal point, with healthy uptake of the product portfolio, particularly G7 and Stelo, despite competitive pressures [3][8] - Improved channel operations and access expansion are likely to have contributed to stronger prescription trends and pharmacy channel throughput [4][6] U.S. Market Dynamics - Strong new patient additions and integration with over 100 health systems have supported smoother prescription workflows [4][5] - Coverage for Type 2 diabetes patients not on insulin has broadened, with access secured through a major PBM, potentially covering around six million lives [4][5] International Trends - The international business has maintained healthy growth, driven by expanding Type 2 access and market penetration in regions like Ontario, France, and Japan [7][10] - Management expects continued international contribution, supported by growing awareness among primary care providers and improving prescription visibility [9][10] Stelo and New Market Initiatives - Stelo is an emerging growth vector, with over 400,000 app downloads and partnerships enhancing user engagement [11][12] - While currently a small financial contributor, Stelo is expected to represent 2% to 3% of 2025 sales, with ongoing feature expansion likely to accelerate adoption [12] Financial Outlook and Margin Progress - The company raised its full-year 2025 revenue outlook to $4.60 to $4.625 billion, reflecting 14% to 15% growth [13] - Gross margin is projected at approximately 62%, with expectations for sequential improvement as freight costs ease and inventory levels normalize [13][14] Estimate Picture - The Zacks Consensus Estimate for Q3 revenues is $1.18 billion, indicating an 18.4% improvement year-over-year, with EPS expected to increase by 26.7% to 57 cents [15] Long-Term Investment Visibility - Dexcom's long-term growth is supported by the expansion of the CGM category into Type 2 and pre-diabetes markets, with improving coverage and digital workflow integration [24][25] - Innovation remains central to the strategy, with advancements in product offerings and software enhancing usability and user engagement [25][26]

Core Points - A shareholder class action lawsuit has been filed against DexCom, alleging that the company made materially false and misleading statements regarding the G6 and G7 devices [1] - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised their reliability and presented health risks to users [1] - The allegations include overstated claims about the enhancements and functionality of the G7, as well as downplaying the severity of issues related to the devices [1] - The lawsuit suggests that these actions have exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [1] Legal Context - Shareholders who purchased DexCom shares between July 26, 2024, and September 17, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is December 26, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. If you currently own DexCom stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal righ. ...

Core Viewpoint - The investigation by Hunterbrook Media highlights significant safety, operational, and financial concerns regarding DexCom, Inc.'s G7 continuous glucose monitor, indicating a decline in the company's reputation and potential risks to patient health [2][5]. Financial Performance - DexCom's share price was $65.41 as of October 15th, with trailing and forward P/E ratios of 46.79 and 25.64 respectively [1]. - Financial indicators suggest deteriorating fundamentals, including a surge in days sales outstanding and a doubling of work-in-process inventory, raising concerns about revenue recognition practices [4]. Product Issues - The G7 sensor's performance has been compromised due to a secret alteration of a key component, leading to underperformance in accuracy metrics and resulting in the FDA classifying the device as "adulterated" [2][3]. - Users have reported serious inaccuracies, leading to hospitalizations and fatalities, including a case linked to a device failure [2][3]. Corporate Culture and Management - Former employees have criticized the corporate culture for prioritizing profit margins over safety, with inadequate technical oversight and rushed design decisions to compete with Abbott's Freestyle Libre 3 [3]. - There are indications of systemic issues within the company, evidenced by executive departures, insider sales, and repeated product recalls [4]. Competitive Landscape - DexCom faces increasing competition from Abbott's superior devices and potential changes in Medicare policies, which could threaten its market share [4]. - The company's own initiatives, such as the Stelo device, are also experiencing accuracy problems and legal challenges [4].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is presented as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI [3][7] - This company is characterized as a "toll booth" operator in the AI energy boom, benefiting from the surge in demand for electricity driven by AI advancements [4][5] Market Position - The company is noted for its unique position in the market, being debt-free and holding a significant cash reserve, which is nearly one-third of its market capitalization [8] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth engines in the AI sector [9][10] Future Trends - The article discusses the broader trends of onshoring and U.S. LNG exports, positioning the company as a beneficiary of these developments under the current political climate [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12] Conclusion - The narrative concludes with a strong call to action for investors to seize the opportunity presented by the AI and energy sectors, emphasizing the potential for significant returns within a short timeframe [15][19]

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, ending the period with double-digit year-to-date gains. In the quarter, the fund’s Investor Class fund ARTMX returned 8.80%, Advisor Class fund APDMX posted a return of 8.80%, and Institutional Class fund APHMX returned 8.83%, compared to a 2.78% return for the Russell Midc ...

Core Viewpoint - Investing in companies that have underperformed but show potential for long-term recovery can yield above-average market returns, exemplified by DexCom and Regeneron Pharmaceuticals, whose shares are down 17% and 21% this year respectively due to company-specific challenges [1]. DexCom - DexCom specializes in continuous glucose monitoring (CGM) systems for diabetes patients, facing challenges such as worse-than-expected financial results and a faster-than-anticipated rebate eligibility impacting revenue [3][4]. - In Q2, DexCom's revenue increased by 15% year-over-year to $1.2 billion, with non-GAAP net earnings per share at $0.48, reflecting an 11.6% increase compared to the previous year, indicating a rebound in financial performance [4]. - The CGM market presents significant growth opportunities, with over 4.5 million insulin patients in the U.S. eligible for coverage but not yet using CGM, and the launch of Stelo as an over-the-counter option for non-insulin patients further expands market potential [6][7]. - DexCom benefits from a network effect due to its large installed base and integration with third-party devices, which could help mitigate tariff threats through a multipronged strategy [7][8]. Regeneron Pharmaceuticals - Regeneron is working to overcome a recent patent cliff, indicating potential for future growth and recovery in its stock performance [8].